RxDoctor Payments Data

Walter Urba

Medical Oncology · Portland, ORNPI 1548253602

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $6,232 of the $6,749 with a category attached, or 92.3%. E.r. Squibb & Sons, L.L.C. accounts for 98.0% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2019 at $6,612 and has fallen 98.4% since, to $104 in 2024.

$6,749in general payments, 2019–2025

Across 20 payments — averaging $337.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$7K
  • Regeneron Healthcare Solutions, Inc.$83
  • Merck$33
  • Daiichi Sankyo Inc.$20
$1,348,349in research payments, 2019–2025

Across 13 payments — averaging $103,719 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AstraZeneca$1M
  • E.r. Squibb & Sons, L.L.C.$260K
  • Merck$41K

What the payments were for

  • Travel & lodging$6,23292%
  • Food & beverage$5188%

General payments by program year

19
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,749 in reported general payments places this provider in the 70th percentile of 92 medical oncology providers in Oregon.

See all medical oncology providers in Oregon →

Other medical oncology in Portland

See the full list for Oregon →

Where these figures come from

Is this you, or does something look wrong? →